Published 3 days ago • loading... • Updated 3 days ago

‘No need’: Orthocell won’t move production to avoid tariffs

Summary by The West Australian

WA biotech Orthocell says there’s no need to shift production to the US to dodge Donald Trump’s tariffs as it wins clearance from the Food and Drug Administration to start selling its nerve repair product.

6 Articles

All

Left

Center

Right

The West Australian

Lean Right

‘No need’: Orthocell won’t move production to avoid tariffs

3 days ago·Australia

Read Full Article

sharecafe.com.au

Hot Stocks: Domain Holdings, Southern Cross Electrical, Orthocell, Mesoblast

On Monday, Domain Holdings Australia (ASX:DHG) entered into an exclusivity and process deed with CoStar Group regarding a revised non-binding indicative proposal to acquire all of Domain’s shares for $4.43 per share in cash. Under the deed, Domain has granted CoStar exclusive access to due diligence materials and confirmed that its directors intend to unanimously recommend the proposal to shareholders—subject to no superior offer emerging and an…

3 days ago

Read Full Article

Stockhead

Lunch Wrap: Tariff storm sinks ASX again, but Orthocell powers ahead with FDA approval

ASX hit hard, around $30 billion wiped off Wall street crashes, tech giants plummet, fear gauge soars Orthocell gets US FDA approval The ASX 200 took another big hit on Friday, down by 1.7% at lunch AEDT as the market erased a further $30 billion-ish from the index on the back of tariff worries. Overnight, Wall Street had its biggest fall since the pandemic’s early days of June 2020, with the S&P 500 plummeting 4.8% and Nasdaq by 5.97%. The s…

3 days ago

Read Full Article

Stocks Down Under

Orthocell (ASX:OCC): All systems go for a US market roll out of its flagship Remplir nerve repair product

Orthocell (ASX:OCC) is the latest ASX biotech to obtain FDA approval. Its nerve repair product Remplir was already approved in Australia, New Zealand and Singapore, plus approval is pending in Canada and Thailand. But the US was the biggest piece of the US$3.5bn pie that is the company’s global addressable market, and now it is…

3 days ago

Read Full Article

fool.com.au

This company has entered a trading halt, is it about to announce FDA approval?

Orthocell Ltd (ASX: OCC) is an Australian medical technology company focused on developing and commercialising innovative regenerative medicine treatments.Â Over the last 12 months its share price has skyrocketed, up more than 260% in that span. For context, S&P/ASX 200 Health Care (ASX: XHJ) is down 3% over that same period. Yesterday, Orthocell shares entered a trading halt at a share price of $1.47. Why was it seeking FDA approval? Orthocell…

3 days ago

Read Full Article

Bazaar Times

Turk Ilaç Receives FDA Approval for GMP-Certified IV Solutions Sales in the U.S.

Turk Ilaç has announced that the U.S. Food and Drug Administration (FDA) has granted approval for the sale of its GMP-certified IV solutions in the United States. FDA Approval and NDC Code Allocation In a statement to the Public Disclosure Platform (KAP), the company stated: “Our GMP-certified IV parenteral solutions, produced under the Turkfleks brand at our Ankara/Akyurt facilities, have been approved for free sale in the U.S. by the FDA. The…

3 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year